What is Medistim ASA's (MEDI.OL) StockRank?

MoatMap's StockRank for Medistim ASA (MEDI.OL) is 86/100, with a Strong Buy signal. This is a composite score combining Quality (87), Value (38), and Momentum (51) factor ranks across MoatMap's 20,000+ stock universe.

Does Medistim ASA have an economic moat?

Medistim ASA (MEDI.OL) has a Quality factor score of 87/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Medistim ASA a buy, hold, or sell?

MoatMap's current signal for Medistim ASA (MEDI.OL) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Medistim ASA in?

Medistim ASA (MEDI.OL) operates in the Healthcare sector, specifically the Medical Devices industry (Norway).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

MEDI.OL

STRONG BUYAPPROVE

Medistim ASA · Healthcare · Norway · $438M · Avg Vol: $801K/d

StockRank

P/E (TTM)

26.9x

ROE

32.1%

D/E

0.1x

Dividend %

3.5%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Medistim is a high-quality medical technology compounder with a near-monopoly (>80% market share) in surgical flow measurement for CABG. Its asset-light model, high ROIC, and regulatory moat make it a perfect Terry Smith compounder, while rising global surgical volumes provide a steady tailwind.

COMPANY DESCRIPTION

Medistim ASA is a global market leader in medical devices that measure blood flow and perform intraoperative ultrasound imaging during cardiac and vascular surgery. The company's proprietary Transit Time Flow Measurement (TTFM) and ultrasound imaging systems help surgeons verify graft patency and reduce surgical risks. Its competitive moat is secured by high global market share, strong clinical validation, and a high-margin recurring revenue stream from single-use surgical probes.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	50.2M	53.8M	58.1M	72.2M	12.9%
EPS	0.65	0.59	0.59	0.90	11.7%
Shares	18.3M	18.3M	18.3M	18.3M	0.0%
Debt	1.8M	1.8M	3.5M	5.1M	42.3%
Equity	37.9M	41.1M	45.1M	48.3M	8.4%
Op CF	11.7M	12.3M	14.8M	19.3M	18.1%
Inv CF	-2.2M	-3.1M	-2.5M	-3.4M	—
Fin CF	-7.3M	-9.4M	-9.4M	-12.7M	—

PRICE (1Y)+2.7%

SMA 50SMA 200

$23.94

RSI (14)

57.4

52W High

$29.08

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

37.9%98.0

ROE

32.1%94.8

GP/Assets

87.8%96.4

Op. Margin

28.3%90.8

FCF/Assets

16.9%94.6

Piotroski

782.3

Int. Cover

50.0x88.4

D/E Ratio

0.07x71.6

Current Ratio

3.80x62.4

Value

P/E (TTM)

26.9x41.0

EV/EBITDA

19.8x30.3

P/FCF

351.0x30.9

P/B

8.3x14.5

P/S

5.8x36.6

Div Yield

3.5%77.0

Momentum

52W High %

82%74.8

RS 6M

-30%45.2

SMA 50/200

0.99x60.0

EPS Rev 4W

-0.2%33.0

EPS Rev 12W

—N/A

EPS Improve

+11%27.7

Q Growth

-7%34.2

FUNDAMENTALS

Market Cap

$438M

P/E (Forward)

24.2x

Gross Margin

80.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MEDI.OL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
MEDI.OL	Medistim ASA(you)	$438M	86	STRONG BUY
PHO.OL	Photocure ASA	$166M	70	BUY
VISTN.OL	Vistin Pharma ASA	$93M	99	STRONG BUY
NYKD.OL	Nykode Therapeutics AS	$109M	46	HOLD
AZT.OL	ArcticZymes Technologies ASA	$107M	45	HOLD
CRNA.OL	Circio Holding ASA	$232M	20	SELL
TRMED.OL	Thor Medical ASA	$157M	20	SELL
ZLNA.OL	Zelluna ASA	$51M	20	SELL

Peer medians: ROE 4.1% · P/E 19.0x · Gross margin 93.6%

Medistim ASA (MEDI.OL) — Stock Score Summary

Medistim ASA (MEDI.OL) has a MoatMap StockRank of 86/100 based on Quality (87/100), Value (38/100), and Momentum (51/100) factor scores. The current signal is STRONG BUY. Medistim is a high-quality medical technology compounder with a near-monopoly (>80% market share) in surgical flow measurement for CABG. Its asset-light model, high ROIC, and regulatory moat make it a perfect Terry Smith compounder, while rising global surgical volumes provide a steady tailwind.

Key Financial Metrics

Price	$23.94
Market Cap	$438M
P/E (TTM)	26.93
P/E (Forward)	24.22
Price/Book	8.30
Return on Equity	32.1%
Return on Invested Capital	37.9%
Debt/Equity	6.83
Gross Margin	80.7%
Operating Margin	28.3%
Revenue Growth	11.1%
Dividend Yield	3.5%
Free Cash Flow	$1M

Medistim ASA operates in the Medical Devices industry, part of the Healthcare sector (Norway).

Frequently Asked Questions

What is Medistim ASA’s (MEDI.OL) StockRank?: MoatMap’s StockRank for Medistim ASA (MEDI.OL) is 86/100, with a Strong Buy signal. It is a composite of Quality (87), Value (38), and Momentum (51) factor ranks across MoatMap’s 20,000+ stock universe.
Does Medistim ASA have an economic moat?: Medistim ASA (MEDI.OL) has a Quality factor score of 87/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Medistim ASA a buy, hold, or sell?: MoatMap’s current signal for Medistim ASA (MEDI.OL) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Medistim ASA in?: Medistim ASA (MEDI.OL) operates in the Healthcare sector, specifically the Medical Devices industry (Norway).